Historical Valuation
Enanta Pharmaceuticals Inc (ENTA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.43 is considered Undervalued compared with the five-year average of 0.88. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 19.36 to 34.06 according to relative valuation methord. Compared to the current price of 13.11 USD , Enanta Pharmaceuticals Inc is Undervalued By 32.3%.
Relative Value
Fair Zone
19.36-34.06
Current Price：13.11
32.3%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Enanta Pharmaceuticals Inc (ENTA) has a current Price-to-Book (P/B) ratio of 4.77. Compared to its 3-year average P/B ratio of 1.93 , the current P/B ratio is approximately 147.40% higher. Relative to its 5-year average P/B ratio of 2.37, the current P/B ratio is about 101.28% higher. Enanta Pharmaceuticals Inc (ENTA) has a Forward Free Cash Flow (FCF) yield of approximately -7.73%. Compared to its 3-year average FCF yield of -38.49%, the current FCF yield is approximately -79.92% lower. Relative to its 5-year average FCF yield of -25.41% , the current FCF yield is about -69.58% lower.
P/B
Median3y
1.93
Median5y
2.37
FCF Yield
Median3y
-38.49
Median5y
-25.41
Competitors Valuation Multiple
AI Analysis for ENTA
The average P/S ratio for ENTA competitors is 33.57, providing a benchmark for relative valuation. Enanta Pharmaceuticals Inc Corp (ENTA.O) exhibits a P/S ratio of 6.43, which is -80.85% above the industry average. Given its robust revenue growth of 3.55%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ENTA
1Y
3Y
5Y
Market capitalization of ENTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ENTA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ENTA currently overvalued or undervalued?
Enanta Pharmaceuticals Inc (ENTA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.43 is considered Undervalued compared with the five-year average of 0.88. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 19.36 to 34.06 according to relative valuation methord. Compared to the current price of 13.11 USD , Enanta Pharmaceuticals Inc is Undervalued By 32.30% .
What is Enanta Pharmaceuticals Inc (ENTA) fair value?
ENTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 19.36 to 34.06 according to relative valuation methord.
How does ENTA's valuation metrics compare to the industry average?
The average P/S ratio for ENTA's competitors is 33.57, providing a benchmark for relative valuation. Enanta Pharmaceuticals Inc Corp (ENTA) exhibits a P/S ratio of 6.43, which is -80.85% above the industry average. Given its robust revenue growth of 3.55%, this premium appears unsustainable.
What is the current P/B ratio for Enanta Pharmaceuticals Inc (ENTA) as of Jan 11 2026?
As of Jan 11 2026, Enanta Pharmaceuticals Inc (ENTA) has a P/B ratio of 4.77. This indicates that the market values ENTA at 4.77 times its book value.
What is the current FCF Yield for Enanta Pharmaceuticals Inc (ENTA) as of Jan 11 2026?
As of Jan 11 2026, Enanta Pharmaceuticals Inc (ENTA) has a FCF Yield of -7.73%. This means that for every dollar of Enanta Pharmaceuticals Inc’s market capitalization, the company generates -7.73 cents in free cash flow.
What is the current Forward P/E ratio for Enanta Pharmaceuticals Inc (ENTA) as of Jan 11 2026?
As of Jan 11 2026, Enanta Pharmaceuticals Inc (ENTA) has a Forward P/E ratio of -4.70. This means the market is willing to pay $-4.70 for every dollar of Enanta Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Enanta Pharmaceuticals Inc (ENTA) as of Jan 11 2026?
As of Jan 11 2026, Enanta Pharmaceuticals Inc (ENTA) has a Forward P/S ratio of 6.43. This means the market is valuing ENTA at $6.43 for every dollar of expected revenue over the next 12 months.